MANNKIND CORP Business Acquisition, Pro Forma Revenue
MANNKIND CORP (MNKD) reported Business Acquisition, Pro Forma Revenue of $48.61 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-07.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2023-08-07
- MANNKIND CORP business acquisition, pro forma revenue for the quarter ending 2023-06-30 was $48.61M, a 94.51% increase year-over-year.
- MANNKIND CORP business acquisition, pro forma revenue for the quarter ending 2023-03-31 was $40.63M, a 124.58% increase year-over-year.
- MANNKIND CORP business acquisition, pro forma revenue for the quarter ending 2022-12-31 was $36.06M, a 93.73% increase year-over-year.
- MANNKIND CORP business acquisition, pro forma revenue for the quarter ending 2022-09-30 was $30.75M, a 9.49% increase year-over-year.
- MANNKIND CORP business acquisition, pro forma revenue for fiscal 2022 was $109.93M, a 11.86% increase from fiscal 2021.
- MANNKIND CORP business acquisition, pro forma revenue for fiscal 2021 was $98.28M.
| Period end | Business Acquisition, Pro Forma Revenue 1 month | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $48.61M 10-Q · filed 2023-08-07 | $89.24M 10-Q · filed 2023-08-07 | $125.30M derived: sum of 3 quarters · filed 2023-08-07 | $156.05M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2023-03-31 | $40.63M 10-Q · filed 2023-05-09 | $76.69M derived: sum of 2 quarters · filed 2023-05-09 | $107.44M derived: sum of 3 quarters · filed 2023-05-09 | $132.43M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-12-31 | $36.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $66.81M derived: sum of 2 quarters · filed 2023-02-23 | $91.80M derived: sum of 3 quarters · filed 2023-08-07 | $109.93M 10-K · filed 2023-02-23 | |
| 2022-09-30 | $30.75M 10-Q · filed 2022-11-08 | $55.74M derived: sum of 2 quarters · filed 2023-08-07 | $73.87M 10-Q · filed 2022-11-08 | $92.45M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-06-30 | $2.10M 10-Q · filed 2022-08-09 | $24.99M 10-Q · filed 2023-08-07 | $43.08M 10-Q · filed 2023-08-07 | $61.70M derived: sum of 3 quarters · filed 2023-08-07 | $89.78M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $18.09M 10-Q · filed 2023-05-09 | $36.70M derived: sum of 2 quarters · filed 2023-05-09 | $64.79M derived: sum of 3 quarters · filed 2023-05-09 | $93.50M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $18.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $46.70M derived: sum of 2 quarters · filed 2023-02-23 | $75.41M derived: sum of 3 quarters · filed 2023-02-23 | $98.28M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $28.09M 10-Q · filed 2022-11-08 | $56.80M derived: sum of 2 quarters · filed 2022-11-08 | $79.67M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $28.71M 10-Q · filed 2022-08-09 | $51.84M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |